Corneal Dystrophies

Editor(s): Lisch W. (Hanau) 
Seitz B. (Homburg/Saar) 
Table of Contents
Vol. 48, 2011
Section title: Paper
Lisch W, Seitz B (eds): Corneal Dystrophies. Dev Ophthalmol. Basel, Karger, 2011, vol 48, pp 67–96

Differential Diagnosis of Schnyder Corneal Dystrophy

Weiss J.S. · Khemichian A.J.
aDepartment of Ophthalmology, Louisiana State University Health Science Center, New Orleans, La.; bKresge Eye Institute, Wayne State University School of Medicine, Detroit, Mich., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Schnyder corneal dystrophy (SCD) is a rare corneal dystrophy characterized by abnormally increased deposition of cholesterol and phospholipids in the cornea leading to progressive vision loss. SCD is inherited as an autosomal dominant trait with high penetrance and has been mapped to the UBIAD1 gene on chromosome 1p36.3. Although 2/3 of SCD patients also have systemic hypercholesterolemia, the incidence of hypercholesterolemia is also increased in unaffected members of SCD pedigrees. Consequently, SCD is thought to result from a local metabolic defect in the cornea. The corneal findings in SCD are very predictable depending on the age of the individual, with initial central corneal haze and/or crystals, subsequent appearance of arcus lipoides in the third decade and formation of midperipheral haze in the late fourth decade. Because only 50% of affected patients have corneal crystals, the International Committee for Classification of Corneal Dystrophies recently changed the original name of this dystrophy from Schnyder crystalline corneal dystrophy to Schnyder corneal dystrophy. Diagnosis of affected individuals without crystalline deposits is often delayed and these individuals are frequently misdiagnosed. The differential diagnosis of the SCD patient includes other diseases with crystalline deposits such as cystinosis, tyrosinemia, Bietti crystalline dystrophy, hyperuricemia/gout, multiple myeloma, monoclonal gammopathy, infectious crystalline keratopathy, and Dieffenbachia keratitis. Depositions from drugs such as gold in chrysiasis, chlorpromazine, chloroquine, and clofazamine can also result in corneal deposits and are different from SCD. Diseases of systemic lipid metabolism that cause corneal opacification, such as lecithin-cholesterol acyltransferase deficiency, fish eye disease and Tangier disease, should also be considered although these are autosomal recessive disorders.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Theendakara V Tromp G Kuivaniemi H , et al: Fine mapping of the schnyder's crystalline corneal dystrophy locus. Hum Genet 2004;114:594-600
  2. Weiss JS Kruth HS Kuivaniemi H , et al: Mutations in the UBIAD1 gene on chromosome short arm 1, region 36, cause schnyder crystalline corneal dystrophy. Invest Ophthalmol Vis Sci 2007;48:5007-5012
  3. Orr A Dube MP Marcadier J Jiang H Federico A George S Seamone C Andrews D Dubord P Holland S: Mutations in the UBIAD1 gene, encoding a potential prenyltransferase, are causal for schnyder crystalline corneal dystrophy. PLoS One 2007;2:e685
  4. Shearman AM Hudson TJ Andresen JM , et al: The gene for schnyder's crystalline corneal dystrophy maps to human chromosome 1p34.1-p36. Hum Mol Genet 1996;5:1667-1672
  5. Gaynor PM Zhang WY Weiss JS , et al: Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in schnyder's corneal dystrophy. Arterioscler Thromb Vasc Biol 1996;16:992-999
  6. Weiss JS: Visual morbidity in thirty-four families with schnyder crystalline corneal dystrophy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007;105:616-648
  7. Brownstein S Jackson WB Onerheim RM: Schnyder's crystalline corneal dystrophy in association with hyperlipoproteinemia: histopathological and ultrastructural findings. Can J Ophthalmol 1991;26:273-279
  8. Bron AJ: Corneal changes in the dislipoproteinaemias. Cornea 1989;8:135-140
  9. McCarthy M Innis S Dubord P White V: Panstromal schnyder corneal dystrophy. A clinical pathologic report with quantitative analysis of corneal lipid composition. Ophthalmology 1994;101:895-901
  10. Lisch W Weidle EG Lisch C , et al: Schnyder's dystrophy. Progression and metabolism. Ophthalmic Paediatr Genet 1986;7:45-56
  11. Barchiesi BJ Eckel RH Ellis PP: The cornea and disorders of lipid metabolism. Surv Ophthalmol 1991;36:1-22
  12. Bron AJ Williams HP Carruthers ME: Hereditary crystalline stromal dystrophy of Schnyder. I. Clinical features of a family with hyperlipoproteinaemia. Br J Ophthalmol 1972;56:383-399
  13. Hoang-Xuan T Pouliquen Y Savoldelli M Gasteau J: Schnyder's crystalline dystrophy. I. Study of a case by light and electron microscopy. J Fr Ophtalmol 1985;8:735-742
  14. Hoang-Xuan T Pouliquen Y Gasteau J: Schnyder's crystalline dystrophy. II. Association with genu valgum. J Fr Ophtalmol 1985;8:743-747
  15. Weiss JS: Schnyder's dystrophy of the cornea. A swede-finn connection. Cornea 1992;11:93-101
  16. Ciancaglini M Carpineto P Doronzo E , et al: Morphological evaluation of schnyder's central crystalline dystrophy by confocal microscopy before and after phototherapeutic keratectomy. J Cataract Refract Surg 2001;27:1892-1895
  17. Jing Y Wang L: Morphological evaluation of schnyder's crystalline corneal dystrophy by laser scanning confocal microscopy and fourier-domain optical coherence tomography. Clin Experiment Ophthalmol 2009;37:308-312
  18. Weiss JS Rodrigues MM Kruth HS , et al: Panstromal schnyder's corneal dystrophy. Ultrastructural and histochemical studies. Ophthalmology 1992;99:1072-1081
  19. Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000;1529:245-256
  20. Norum KR Gjone E: Familial serum-cholesterol esterification failure. A new inborn error of metabolism. Biochim Biophys Acta 1967;144:698-700
  21. Horl G Kroisel PM Wagner E , et al: Compound heterozygosity (G71R/R140H) in the lecithin: cholesterol acyltransferase (LCAT) gene results in an intermediate phenotype between LCAT-deficiency and fish-eye disease. Atherosclerosis 2006;187:101-109
  22. McLean J Fielding C Drayna D , et al: Cloning and expression of human lecithin-cholesterol acyl-transferase cDNA. Proc Natl Acad Sci USA 1986;83:2335-2339
  23. Azoulay M Henry I Tata F , et al: The structural gene for lecithin:cholesterol acyl transferase (LCAT) maps to 16q22. Ann Hum Genet 1987;51:129-136
  24. Kralovicova J Lei H Vorechovsky I: Phenotypic consequences of branch point substitutions. Hum Mutat 2006;27:803-813
  25. Alawadhi M Thanassoulis G Marcil M Genest J: Genetic lipoprotein disorders and coronary atherosclerosis. Curr Atheroscler Rep 2005;7:196-203
  26. Funke H von Eckardstein A Pritchard PH , et al: Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest 1993;91:677-683
  27. Weidle EG Lisch W: Corneal opacity as the leading symptom of hereditary lecithin-cholesterol acyl-transferase (LCAT) deficiency. Case report and a review of the literature. Klin Monatsbl Augenheilkd 1987;190:182-187
  28. Schmidt HH Diekstall FF Bojanovski D Manns MP: Fish eye disease. Dtsch Med Wochenschr 1994;119:1393-1396
  29. Clerc M Pouliquen Y: Arcus juvenilis and lecithin:cholesterol acyltransferase functions. Report of a case of familial fish-eye-disease. Bull Acad Natl Med 1993;177:807-820
  30. McIntyre N: Familial LCAT deficiency and fish-eye disease. J Inherit Metab Dis 1988;11:(suppl 1)45-56
  31. Chu FC Kuwabara T Cogan DG Schaefer EJ Brewer HB: Ocular manifestations of familial high-density lipoprotein deficiency (Tangier disease). Arch Ophthalmol 1979;97:1926-1928
  32. Frohlich J Hoag G McLeod R , et al: Hypoalphalipoproteinemia resembling fish eye disease. Acta Med Scand 1987;221:291-298
  33. Kastelein JJ Pritchard PH Erkelens DW , et al: Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of dutch descent. J Intern Med 1992;231:413-419
  34. Carlson LA: Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia. Eur J Clin Invest 1982;12:41-43
  35. Clerc M Dumon MF Sess D , et al: A ‘Fish-eye disease’ familial condition with massive corneal opacities and hypoalphalipoproteinaemia: clinical, biochemical and genetic features. Eur J Clin Invest 1991;21:616-624
  36. Kohnen T Pelton RW Jones DB: Schnyder corneal dystrophy and juvenile, systemic hypercholesteremia. Klin Monatsbl Augenheilkd 1997;211:135-137
  37. Borven I Egge K Gjone E: Corneal and fundus changes in familial LCAT-deficiency. Acta Ophthalmol (Copenh) 1974;52:201-210
  38. Berard AM Clerc M Brewer B Santamarina-Fojo S: A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Clin Chim Acta 2001;314:131-139
  39. De Smedt M Van Ginderdeuren R De Vos R , et al: Corneal opacifications in a low high density lipoprotein syndrome: suspicion of fish eye disease: a case report. Bull Soc Belge Ophtalmol 2001;25-30
  40. Herrmann WA von Mohrenfels CW Lohmann CP: Confocal microscopy and corneal sensitivity in a patient with corneal manifestations of Tangier disease. Cornea 2004;23:825-827
  41. Rust S Rosier M Funke H , et al: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352-355
  42. Rust S Walter M Funke H , et al: Assignment of tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet 1998;20:96-98
  43. Remaley AT Rust S Rosier M , et al: Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original tangier disease kindred. Proc Natl Acad Sci U S A 1999;96:12685-12690
  44. Pietrini V Rizzuto N Vergani C , et al: Neuropathy in tangier disease: A clinicopathologic study and a review of the literature. Acta Neurol Scand 1985;72:495-505
  45. Schippling S Orth M Beisiegel U , et al: Severe tangier disease with a novel ABCA1 gene mutation. Neurology 2008;71:1454-1454
  46. Brooks-Wilson A Marcil M Clee SM , et al: Mutations in ABC1 in tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336-345
  47. Schaefer EJ Zech LA Schwartz DE Brewer HB: Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980;93:261-266
  48. Pressly TA Scott WJ Ide CH , et al: Ocular complications of tangier disease. Am J Med 1987;83:991-994
  49. Chu FC Kuwabara T Cogan DG , et al: Ocular manifestations of familial high-density lipoprotein deficiency (tangier disease). Arch Ophthalmol 1979;97:1926-1928
  50. Schneider JA Bradley K Seegmiller JE: Increased cystine in leukocytes from individuals homozygous and heterozygous for cystinosis. Science 1967;157:1321-1322
  51. Kalatzis V Cherqui S Antignac C Gasnier B: Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J 2001;20:5940-5949
  52. Attard M Jean G Forestier L , et al: Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 1999;8:2507-2514
  53. Kalatzis V Nevo N Cherqui S , et al: Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet 2004;13:1361-1371
  54. Kleta R Anikster Y Lucero C , et al: CTNS mutations in african american patients with cystinosis. Mol Genet Metab 2001;74:332-337
  55. Bois E Feingold J Frenay P Briard ML: Infantile cystinosis in france: genetics, incidence, geographic distribution. J Med Genet 1976;13:434-438
  56. Wen SF Friedman AL Oberley TD: Two case studies from a family with primary Fanconi syndrome. Am J Kidney Dis 1989;13:240-246
  57. Gahl WA Thoene JG Schneider JA: Cystinosis. N Engl J Med 2002;347:111 -121
  58. Katz B Melles RB Schneider JA: Contrast sensitivity function in nephropathic cystinosis. Arch Ophthalmol 1987;105:1667-1669
  59. Labbe A Niaudet P Loirat C , et al: In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis. Ophthalmology 2009;116:870-876
  60. Gahl WA Kuehl EM Iwata F , et al: Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000;71:100-120
  61. Brubaker RF Wong VG Schulman JD , et al: Benign cystinosis. The clinical, biochemical and morphologic findings in a family with two affected siblings. Am J Med 1970;49:546-550
  62. Tsilou ET Rubin BI Reed G , et al: Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology 2006;113:1002-1009
  63. Kimonis VE Troendle J Rose SR , et al: Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 1995;80:3257-3261
  64. Kaiser-Kupfer MI Fujikawa L Kuwabara T , et al: Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med 1987;316:775-779
  65. da Silva VA Zurbrugg RP Lavanchy P , et al: Long-term treatment of infantile nephropathic cystinosis with cysteamine. N Engl J Med 1985;313:1460-1463
  66. Tallab TM: Richner-Hanhart syndrome importance of early diagnosis and early intervention. J Am Acad Dermatol 1996;35:857-859
  67. Hanhart E: [Not Available]. Dermatologica 1947;94:286-308
  68. Fellman JH Vanbellinghen PJ Jones RT Koler RD: Soluble and mitochondrial forms of tyrosine aminotransferase. Relationship to human tyrosinemia. Biochemistry 1969;8:615-622
  69. Rabinowitz LG Williams LR Anderson CE , et al: Painful keratoderma and photophobia: hallmarks of tyrosinemia type II. J Pediatr 1995;126:266-269
  70. Goldsmith LA: Tyrosinemia II. Int J Dermatol 1985;24:293-294
  71. Tsai CP Lin PY Lee NC , et al: Corneal lesion as the initial manifestation of tyrosinemia type II. J Chin Med Assoc 2006;69:286-288
  72. Macsai MS Schwartz TL Hinkle D , et al: Tyrosinemia type II: nine cases of ocular signs and symptoms. Am J Ophthalmol 2001;132:522-527
  73. al-Hemidan AI al-Hazzaa SA: Richner-hanhart syndrome (tyrosinemia type II). Case report and literature review. Ophthalmic Genet 1995;16:21-26
  74. Machino H Miki Y Kawatsu T , et al: Successful dietary control of tyrosinemia II. J Am Acad Dermatol 1983;9:533-539
  75. Godde-Jolly D Larregue M Roussat B Van Effenterre G: A case of richner-hanhart syndrome (tyrosinosis with ocular, cutaneous and mental manifestations. J Fr Ophtalmol 1979;2:23-28
  76. Li A Jiao X Munier FL , et al: Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet 2004;74:817-826
  77. Jiao X Munier FL Iwata F , et al: Genetic linkage of bietti crystallin corneoretinal dystrophy to chromosome 4q35. Am J Hum Genet 2000;67:1309-1313
  78. Lee J Jiao X Hejtmancik JF , et al: The metabolism of fatty acids in human bietti crystalline dystrophy. Invest Ophthalmol Vis Sci 2001;42:1707-1714
  79. Nakano M Kelly EJ Rettie AE: Expression and characterization of CYP4V2 as a fatty acid {omega}-hydroxylase. Drug Metab Dispos 2009;
  80. Kaiser-Kupfer MI Chan CC Markello TC , et al: Clinical biochemical and pathologic correlations in bietti's crystalline dystrophy. Am J Ophthalmol 1994;118:569-582
  81. Harrison RJ Acheson RR Dean-Hart JC: Bietti's tapetoretinal degeneration with marginal corneal dystrophy (crystalline retinopathy): Case report. Br J Ophthalmol 1987;71:220-223
  82. Hu D-N: Ophthalmic genetics in china. Ophthal Paediat Genet 1983;2:39-45
  83. Chaker N Mghaieth F Baccouri R , et al: Clinical and angiographic characteristics of Bietti's corneo-retinal dystrophy: A case study of an 8-year-old girl. J Fr Ophtalmol 2007;30:39-43
  84. Fong AM Koh A Lee K Ang CL: Bietti's crystalline dystrophy in Asians: Clinical, angiographic and electrophysiological characteristics. Int Ophthalmol 2008;
  85. Meyer CH Rodrigues EB Mennel S Schmidt JC: Optical coherence tomography in a case of Bietti's crystalline dystrophy. Acta Ophthalmol Scand 2004;82:609-612
  86. Lai TY Ng TK Tam PO , et al: Genotype phenotype analysis of bietti's crystalline dystrophy in patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci 2007;48:5212-5220
  87. Bernauer W Daicker B: Bietti's corneal-retinal dystrophy. A 16-year progression. Retina 1992;12:18-20
  88. Cheng LS Chiang SL Tu HP , et al: Genomewide scan for gout in taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet 2004;75:498-503
  89. Hoefnagel D Andrew ED Mireault NG Berndt WO: Hereditary choreoathetosis, self-mutilation and hyperuricemia in young males. N Engl J Med 1965;273:130-135
  90. Martinon F Petrilli V Mayor A , et al: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241
  91. Liote F Ea HK: Recent developments in crystal-induced inflammation pathogenesis and management. Curr Rheumatol Rep 2007;9:243-250
  92. Meyers OL Monteagudo FS: Gout in females: an analysis of 92 patients. Clin Exp Rheumatol 1985;3:105-109
  93. Puig JG Michan AD Jimenez ML , et al: Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991;151:726-732
  94. Akahoshi T Murakami Y Kitasato H: Recent advances in crystal-induced acute inflammation. Curr Opin Rheumatol 2007;19:146-150
  95. Wallace SL Singer JZ Duncan GJ , et al: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-269
  96. Lo WR Broocker G Grossniklaus HE: Histopathologic examination of conjunctival tophi in gouty arthritis. Am J Ophthalmol 2005;140:1152-1154
  97. Coassin M Piovanetti O Stark WJ Green WR: Urate deposition in the iris and anterior chamber. Ophthalmology 2006;113:462-465
  98. Ferry AP Safir A Melikian HE: Ocular abnormalities in patients with gout. Ann Ophthalmol 1985;17:632-635
  99. Bernad B Narvaez J Diaz-Torne C , et al: Clinical image: corneal tophus deposition in gout. Arthritis Rheum 2006;54:1025
  100. Slansky HH Kubara T: Intranuclear urate crystals in corneal epithelium. Arch Ophthalmol 1968;80:338-844
  101. Terkeltaub R: Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther 2009;11:236
  102. Orellana J Friedman AH: Ocular manifestations of multiple myeloma, Waldenstrom's macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 1981;26:157-169
  103. Harrison CJ Mazzullo H Ross FM , et al: Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002;117:427-435
  104. Takimoto M Ogawa K Kato Y , et al: Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF. Int J Hematol 2008;87:260-265
  105. Terpos E Cibeira MT Blade J Ludwig H: Management of complications in multiple myeloma. Semin Hematol 2009;46:176-189
  106. Kyle RA Yee GC Somerfield MR , et al: American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472
  107. Muszytowski M Nowak J Wojnicz M , et al: Treatment of multiple myeloma associated anemia with human recombinant erythropoietin in a hemodialysis patient. Pol Arch Med Wewn 1995;93:77-79
  108. Bourne WM Kyle RA Brubaker RF Greipp PR: Incidence of corneal crystals in the monoclonal gammopathies. Am J Ophthalmol 1989;107:192-193
  109. Steuhl KP Knorr M Rohrbach JM , et al: Paraproteinemic corneal deposits in plasma cell myeloma. Am J Ophthalmol 1991;111:312-318
  110. Cherry PM Kraft S McGowan H , et al: Corneal and conjunctival deposits in monoclonal gammopathy. Can J Ophthalmol 1983;18:143-149
  111. Klintworth GK Bredehoeft SJ Reed JW: Analysis of corneal crystalline deposits in multiple myeloma. Am J Ophthalmol 1978;86:303-313
  112. Perry HD Donnenfeld ED Font RL: Intraepithelial corneal immunoglobulin crystals in IgG-kappa multiple myeloma. Cornea 1993;12:448-450
  113. Kleta R Blair SC Bernardini I , et al: Keratopathy of multiple myeloma masquerading as corneal crystals of ocular cystinosis. Mayo Clin Proc 2004;79:410-412
  114. Knapp AJ Gartner S Henkind P: Multiple myeloma and its ocular manifestations. Surv Ophthalmol 1987;31:343-351
  115. Sasaki H Kato T Murakami A , et al: A case of monoclonal gammopathy with corneal stroma deposits. Nippon Ganka Gakkai Zasshi 2006;110:307-311
  116. Kato T Nakayasu K Omata Y , et al: Corneal deposits as an alerting sign of monoclonal gammopathy: a case report. Cornea 1999;18:734-738
  117. Garibaldi DC Gottsch J de la Cruz Z , et al: Immunotactoid keratopathy: a clinicopathologic case report and a review of reports of corneal involvement in systemic paraproteinemias. Surv Ophthalmol 2005;50:61-80
  118. Ormerod LD Collin HB Dohlman CH , et al: Paraproteinemic crystalline keratopathy. Ophthalmology 1988;95:202-212
  119. Hawkins AS Stein RM Gaines BI Deutsch TA: Ocular deposition of copper associated with multiple myeloma. Am J Ophthalmol 2001;131:257-259
  120. Martin NF Kincaid MC Stark WJ , et al: Ocular copper deposition associated with pulmonary carcinoma, IgG monoclonal gammopathy and hypercupremia. A clinicopathologic correlation. Ophthalmology 1983;90:110-116
  121. Kyle RA: ‘Benign monoclonal gammopathy. A misnomer? JAMA 1984;251:1849-1854
  122. Gorovoy MS Stern GA Hood CI Allen C: Intrastromal noninflammatory bacterial colonization of a corneal graft. Arch Ophthalmol 1983;101:1749-1752
  123. Dunn S Maguen E Rao NA: Noninflammatory bacterial infiltration of a corneal graft. Cornea 1985;4:189-193
  124. Khater TT Jones DB Wilhelmus KR: Infectious crystalline keratopathy caused by gram-negative bacteria. Am J Ophthalmol 1997;124:19-23
  125. Matoba AY O'Brien TP Wilhelmus KR Jones DB: Infectious crystalline keratopathy due to Streptococcus pneumoniae. Possible association with serotype. Ophthalmology 1994;101:1000-1004
  126. Connell B Armstrong M Tullo A: A case of recurrent infectious crystalline keratopathy secondary to Haemophilus influenzae. Eye 2007;21:427-428
  127. Hu FR: Infectious crystalline keratopathy caused by mycobacterium fortuitum and oseudomonas aeruginosa. Am J Ophthalmol 1990;109:738-739
  128. Wilhelmus KR Robinson NM: Infectious crystalline keratopathy caused by candida albicans. Am J Ophthalmol 1991;112:322-325
  129. Tu EY Joslin CE Nijm LM , et al: Polymicrobial keratitis: Acanthamoeba and infectious crystalline keratopathy. Am J Ophthalmol 2009;148:13-19 e2
  130. Meisler DM Langston RH Naab TJ , et al: Infectious crystalline keratopathy. Am J Ophthalmol 1984;97:337-343
  131. Sridhar MS Sharma S Garg P Rao GN: Epithelial infectious crystalline keratopathy. Am J Ophthalmol 2001;131:255-257
  132. Samples JR Baumgartner SD Binder PS: Infectious crystalline keratopathy: an electron microscope analysis. Cornea 1985;4:118-126
  133. Ainbinder DJ Parmley VC Mader TH Nelson ML: Infectious crystalline keratopathy caused by candida guilliermondii. Am J Ophthalmol 1998;125:723-725
  134. Sharma N Vajpayee RB Pushker N Vajpayee M: Infectious crystalline keratopathy. CLAO J 2000;26:40-43
  135. James CB McDonnell PJ Falcon MG: Infectious crystalline keratopathy. Br J Ophthalmol 1988;72:628-630
  136. Rauber A: Observations on the idioblasts of dieffenbachia. J Toxicol Clin Toxicol 1985;23:79-90
  137. Chiou AG Cadez R Bohnke M: Diagnosis of dieffenbachia induced corneal injury by confocal microscopy. Br J Ophthalmol 1997;81:168-169
  138. Matysik A: Harmful impact of diffenbachia sap on the anterior segment of the eye. Klin Oczna 1996;98:311-314
  139. Egerer I: Ocular involvement due to the juice of dieffenbachia plants (author's transl). Klin Monatsbl Augenheilkd 1977;170:128-130
  140. Tierney DW: Ocular chrysiasis. J Am Optom Assoc 1988;59:960-962
  141. Grubb BR Matthews DO Bentley PJ: Ocular chrysiasis: accumulation of gold in the rabbit eye. Curr Eye Res 1986;5:891-893
  142. Kincaid MC Green WR Hoover RE Schenck PH: Ocular chrysiasis. Arch Ophthalmol 1982;100:1791-1794
  143. Lopez JD del Castillo JM Lopez CD Sanchez JG: Confocal microscopy in ocular chrysiasis. Cornea 2003;22:573-575
  144. Singh AD Puri P Amos RS: Deposition of gold in ocular structures, although known, is rare. A case of ocular chrysiasis in a patient of rheumatoid arthritis on gold treatment is presented. Eye 2004;18:443-444
  145. Phua YS Patel DV McGhee CN: In vivo confocal microstructural analysis of corneal endothelial changes in a patient on long-term chlorpromazine therapy. Graefes Arch Clin Exp Ophthalmol 2005;243:721-723
  146. Webber SK Domniz Y Sutton GL , et al: Corneal deposition after high-dose chlorpromazine hydrochloride therapy. Cornea 2001;20:217-219
  147. Razeghinejad MR Nowroozzadeh MH Zamani M Amini N: In vivo observations of chlorpromazine ocular deposits in a patient on long-term chlorpromazine therapy. Clin Experiment Ophthalmol 2008;36:560-563
  148. Coyle JT: Hydroxychloroquine retinopathy. Ophthalmology 2001;108:243-244
  149. Lyons JS Severns ML: Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007;143:801-809
  150. Slowik C Somodi S von Gruben C , et al: Detection of morphological corneal changes caused by chloroquine therapy using confocal in vivo microscopy. Ophthalmologe 1997;94:147-151
  151. Dosso A Rungger-Brandle E: In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 2007;245:318-320
  152. Mavrikakis I Sfikakis PP Mavrikakis E , et al: The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003;110:1321-1326
  153. Sritharan M: Studies on the tissue distribution of liposome-associated clofazimine, an antileprosy drug. Methods Find Exp Clin Pharmacol 1993;15:107-111
  154. Kaur I Ram J Kumar B , et al: Effect of clofazimine on eye in multibacillary leprosy. Indian J Lepr 1990;62:87-90
  155. Font RL Sobol W Matoba A: Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. Ophthalmology 1989;96:311-315
  156. Walinder PE Gip L Stempa M: Corneal changes in patients treated with clofazimine. Br J Ophthalmol 1976;60:526-528

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50